Fate Therapeutics (FATE) to Release Earnings on Thursday

Fate Therapeutics (NASDAQ:FATE - Get Free Report) will be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Fate Therapeutics to post earnings of ($0.48) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12. The firm had revenue of $1.68 million during the quarter, compared to analysts' expectations of $0.85 million. Fate Therapeutics had a negative net margin of 253.30% and a negative return on equity of 38.17%. During the same period in the prior year, the company earned ($0.58) EPS. On average, analysts expect Fate Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fate Therapeutics Trading Down 8.1 %

Shares of FATE traded down $0.34 during midday trading on Tuesday, reaching $3.88. 1,983,083 shares of the company were exchanged, compared to its average volume of 2,808,477. The stock has a 50-day moving average price of $6.23 and a 200-day moving average price of $4.71. The company has a market cap of $441.62 million, a price-to-earnings ratio of -2.37 and a beta of 1.80. Fate Therapeutics has a 1-year low of $1.63 and a 1-year high of $8.83.

Analyst Upgrades and Downgrades

FATE has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research report on Thursday, April 11th. Morgan Stanley raised their target price on Fate Therapeutics from $3.00 to $7.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 27th. HC Wainwright restated a "neutral" rating and set a $7.00 price target on shares of Fate Therapeutics in a research report on Tuesday, March 19th. Bank of America lifted their price objective on shares of Fate Therapeutics from $2.00 to $6.00 and gave the company an "underperform" rating in a research report on Thursday, March 28th. Finally, Wedbush restated a "neutral" rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Monday. One analyst has rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Fate Therapeutics presently has an average rating of "Hold" and an average price target of $6.90.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.